Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Certolizumab Pegol in Rheumatoid Arthritis
NCT00160693Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2003
- Primary completion
- Feb 2011
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Mar 2003; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00160693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160693.